Gilead Sciences, Inc. (NASDAQ:GILD) Stock Holdings Boosted by Raleigh Capital Management Inc.

Raleigh Capital Management Inc. increased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 30.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 33,197 shares of the biopharmaceutical company’s stock after buying an additional 7,801 shares during the quarter. Gilead Sciences comprises approximately 1.1% of Raleigh Capital Management Inc.’s holdings, making the stock its 15th largest position. Raleigh Capital Management Inc.’s holdings in Gilead Sciences were worth $2,783,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Sumitomo Life Insurance Co. boosted its stake in shares of Gilead Sciences by 0.7% during the 3rd quarter. Sumitomo Life Insurance Co. now owns 17,822 shares of the biopharmaceutical company’s stock worth $1,494,000 after acquiring an additional 117 shares in the last quarter. Sivia Capital Partners LLC raised its holdings in Gilead Sciences by 3.9% during the 3rd quarter. Sivia Capital Partners LLC now owns 3,249 shares of the biopharmaceutical company’s stock worth $272,000 after buying an additional 123 shares during the period. Roberts Wealth Advisors LLC lifted its stake in Gilead Sciences by 1.9% during the third quarter. Roberts Wealth Advisors LLC now owns 7,035 shares of the biopharmaceutical company’s stock valued at $599,000 after buying an additional 130 shares in the last quarter. Wagner Wealth Management LLC boosted its holdings in shares of Gilead Sciences by 1.7% in the third quarter. Wagner Wealth Management LLC now owns 8,026 shares of the biopharmaceutical company’s stock worth $673,000 after buying an additional 135 shares during the period. Finally, Institute for Wealth Management LLC. raised its holdings in shares of Gilead Sciences by 1.9% during the second quarter. Institute for Wealth Management LLC. now owns 7,551 shares of the biopharmaceutical company’s stock valued at $518,000 after acquiring an additional 142 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, insider Johanna Mercier sold 29,357 shares of the firm’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the sale, the insider now directly owns 78,127 shares in the company, valued at approximately $6,545,480.06. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. In other news, insider Johanna Mercier sold 29,357 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the transaction, the insider now directly owns 78,127 shares in the company, valued at approximately $6,545,480.06. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total transaction of $167,660.00. Following the completion of the sale, the insider now directly owns 100,189 shares of the company’s stock, valued at approximately $8,398,843.87. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 36,847 shares of company stock valued at $3,033,340. 0.16% of the stock is currently owned by corporate insiders.

Gilead Sciences Stock Down 0.5 %

Shares of GILD opened at $86.29 on Tuesday. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $87.86. The firm has a market capitalization of $107.50 billion, a P/E ratio of 239.69, a P/E/G ratio of 2.98 and a beta of 0.18. The company has a 50-day simple moving average of $81.32 and a 200-day simple moving average of $72.94. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.95 and a current ratio of 1.14.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.61 by $0.40. The company had revenue of $6.95 billion for the quarter, compared to analyst estimates of $6.64 billion. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. On average, equities research analysts expect that Gilead Sciences, Inc. will post 3.78 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 27th. Shareholders of record on Friday, September 13th were given a $0.77 dividend. The ex-dividend date was Friday, September 13th. This represents a $3.08 annualized dividend and a yield of 3.57%. Gilead Sciences’s payout ratio is 855.56%.

Wall Street Analyst Weigh In

GILD has been the topic of several research analyst reports. Raymond James upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 price objective on the stock in a research report on Monday, July 8th. Evercore ISI upgraded Gilead Sciences to a “strong-buy” rating in a report on Friday, August 9th. JPMorgan Chase & Co. increased their price objective on Gilead Sciences from $95.00 to $100.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 9th. Piper Sandler reaffirmed an “overweight” rating and set a $95.00 target price on shares of Gilead Sciences in a research note on Wednesday, September 11th. Finally, Leerink Partners raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and increased their price target for the stock from $74.00 to $96.00 in a research report on Monday. Ten equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $86.85.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.